Loading…
Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan
Objective The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data...
Saved in:
| Published in: | Modern rheumatology 2012-09, Vol.22 (5), p.712-719 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063 |
| container_end_page | 719 |
| container_issue | 5 |
| container_start_page | 712 |
| container_title | Modern rheumatology |
| container_volume | 22 |
| creator | Suematsu, Rie Ohta, Akihide Matsuura, Emi Takahashi, Hiroki Fujii, Takao Horiuchi, Takahiko Minota, Seiji Ishigatsubo, Yoshiaki Ota, Toshiyuki Takei, Shuji Soejima, Sachiko Inoue, Hisako Koarada, Syuichi Tada, Yoshifumi Nagasawa, Kohei |
| description | Objective
The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed.
Method
Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively.
Results
Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate.
Conclusion
Tocilizumab may be a promising biologic agent in refractory ASD. |
| doi_str_mv | 10.1007/s10165-011-0569-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1039882489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3004478821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063</originalsourceid><addsrcrecordid>eNpdkc9KxDAQxoMo7rr6AF4k4MVLNdM0aeNNFv-y4MH1HNI03c3SfzYp4s3X8PV8ElPWBfE0M8xvPj7mQ-gUyCUQkl45IMBZRAAiwriI-B6aQkJFlHIi9nc9E2yCjpzbEEKZyMQhmsQxcJIlbIqa5dr0qjODtxr3xnVt4wxuS9wpb03jHX63fo1VMVQev3hbVd-fXw4X1hkVQN_i3LZVuwrXajXy17gOqNWhN_2oGCaHbYOfVKeaY3RQqsqZk986Q693t8v5Q7R4vn-c3ywiTTPqo1QokeVQUC5GowIKXZJcMwCd5EUSM60U57nKDNcJBUrLBArDBJSlYEA4naGLrW7Xt2-DcV7W1mlTVaox7eAkECqyLE4yEdDzf-imHfomuJNAUyBJnJI0UGe_1JDXppBdb2vVf8jdJwMQbwEXVs3K9H9kiBzjktu4ZIhLjnFJTn8AtbqGzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1371042707</pqid></control><display><type>article</type><title>Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan</title><source>Oxford Journals Online</source><creator>Suematsu, Rie ; Ohta, Akihide ; Matsuura, Emi ; Takahashi, Hiroki ; Fujii, Takao ; Horiuchi, Takahiko ; Minota, Seiji ; Ishigatsubo, Yoshiaki ; Ota, Toshiyuki ; Takei, Shuji ; Soejima, Sachiko ; Inoue, Hisako ; Koarada, Syuichi ; Tada, Yoshifumi ; Nagasawa, Kohei</creator><creatorcontrib>Suematsu, Rie ; Ohta, Akihide ; Matsuura, Emi ; Takahashi, Hiroki ; Fujii, Takao ; Horiuchi, Takahiko ; Minota, Seiji ; Ishigatsubo, Yoshiaki ; Ota, Toshiyuki ; Takei, Shuji ; Soejima, Sachiko ; Inoue, Hisako ; Koarada, Syuichi ; Tada, Yoshifumi ; Nagasawa, Kohei</creatorcontrib><description>Objective
The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed.
Method
Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively.
Results
Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate.
Conclusion
Tocilizumab may be a promising biologic agent in refractory ASD.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1007/s10165-011-0569-6</identifier><identifier>PMID: 22160845</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adolescent ; Adult ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis ; C-Reactive Protein - analysis ; Child ; Drug Substitution ; Drug therapy ; Effectiveness ; Etanercept ; Female ; Ferritins - blood ; Humans ; Immunoglobulin G - therapeutic use ; Infliximab ; Kaplan-Meier Estimate ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Original Article ; Orthopedics ; Patients ; Receptors, Tumor Necrosis Factor - therapeutic use ; Retrospective Studies ; Rheumatology ; Still's Disease, Adult-Onset - blood ; Still's Disease, Adult-Onset - drug therapy ; Treatment Outcome ; Young Adult</subject><ispartof>Modern rheumatology, 2012-09, Vol.22 (5), p.712-719</ispartof><rights>Japan College of Rheumatology 2011</rights><rights>Copyright Springer Science & Business Media Sep 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063</citedby><cites>FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22160845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suematsu, Rie</creatorcontrib><creatorcontrib>Ohta, Akihide</creatorcontrib><creatorcontrib>Matsuura, Emi</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Horiuchi, Takahiko</creatorcontrib><creatorcontrib>Minota, Seiji</creatorcontrib><creatorcontrib>Ishigatsubo, Yoshiaki</creatorcontrib><creatorcontrib>Ota, Toshiyuki</creatorcontrib><creatorcontrib>Takei, Shuji</creatorcontrib><creatorcontrib>Soejima, Sachiko</creatorcontrib><creatorcontrib>Inoue, Hisako</creatorcontrib><creatorcontrib>Koarada, Syuichi</creatorcontrib><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Nagasawa, Kohei</creatorcontrib><title>Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><addtitle>Mod Rheumatol</addtitle><description>Objective
The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed.
Method
Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively.
Results
Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate.
Conclusion
Tocilizumab may be a promising biologic agent in refractory ASD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>C-Reactive Protein - analysis</subject><subject>Child</subject><subject>Drug Substitution</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Etanercept</subject><subject>Female</subject><subject>Ferritins - blood</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Infliximab</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Still's Disease, Adult-Onset - blood</subject><subject>Still's Disease, Adult-Onset - drug therapy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpdkc9KxDAQxoMo7rr6AF4k4MVLNdM0aeNNFv-y4MH1HNI03c3SfzYp4s3X8PV8ElPWBfE0M8xvPj7mQ-gUyCUQkl45IMBZRAAiwriI-B6aQkJFlHIi9nc9E2yCjpzbEEKZyMQhmsQxcJIlbIqa5dr0qjODtxr3xnVt4wxuS9wpb03jHX63fo1VMVQev3hbVd-fXw4X1hkVQN_i3LZVuwrXajXy17gOqNWhN_2oGCaHbYOfVKeaY3RQqsqZk986Q693t8v5Q7R4vn-c3ywiTTPqo1QokeVQUC5GowIKXZJcMwCd5EUSM60U57nKDNcJBUrLBArDBJSlYEA4naGLrW7Xt2-DcV7W1mlTVaox7eAkECqyLE4yEdDzf-imHfomuJNAUyBJnJI0UGe_1JDXppBdb2vVf8jdJwMQbwEXVs3K9H9kiBzjktu4ZIhLjnFJTn8AtbqGzQ</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Suematsu, Rie</creator><creator>Ohta, Akihide</creator><creator>Matsuura, Emi</creator><creator>Takahashi, Hiroki</creator><creator>Fujii, Takao</creator><creator>Horiuchi, Takahiko</creator><creator>Minota, Seiji</creator><creator>Ishigatsubo, Yoshiaki</creator><creator>Ota, Toshiyuki</creator><creator>Takei, Shuji</creator><creator>Soejima, Sachiko</creator><creator>Inoue, Hisako</creator><creator>Koarada, Syuichi</creator><creator>Tada, Yoshifumi</creator><creator>Nagasawa, Kohei</creator><general>Springer Japan</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan</title><author>Suematsu, Rie ; Ohta, Akihide ; Matsuura, Emi ; Takahashi, Hiroki ; Fujii, Takao ; Horiuchi, Takahiko ; Minota, Seiji ; Ishigatsubo, Yoshiaki ; Ota, Toshiyuki ; Takei, Shuji ; Soejima, Sachiko ; Inoue, Hisako ; Koarada, Syuichi ; Tada, Yoshifumi ; Nagasawa, Kohei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>C-Reactive Protein - analysis</topic><topic>Child</topic><topic>Drug Substitution</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Etanercept</topic><topic>Female</topic><topic>Ferritins - blood</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Infliximab</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Still's Disease, Adult-Onset - blood</topic><topic>Still's Disease, Adult-Onset - drug therapy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suematsu, Rie</creatorcontrib><creatorcontrib>Ohta, Akihide</creatorcontrib><creatorcontrib>Matsuura, Emi</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Fujii, Takao</creatorcontrib><creatorcontrib>Horiuchi, Takahiko</creatorcontrib><creatorcontrib>Minota, Seiji</creatorcontrib><creatorcontrib>Ishigatsubo, Yoshiaki</creatorcontrib><creatorcontrib>Ota, Toshiyuki</creatorcontrib><creatorcontrib>Takei, Shuji</creatorcontrib><creatorcontrib>Soejima, Sachiko</creatorcontrib><creatorcontrib>Inoue, Hisako</creatorcontrib><creatorcontrib>Koarada, Syuichi</creatorcontrib><creatorcontrib>Tada, Yoshifumi</creatorcontrib><creatorcontrib>Nagasawa, Kohei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suematsu, Rie</au><au>Ohta, Akihide</au><au>Matsuura, Emi</au><au>Takahashi, Hiroki</au><au>Fujii, Takao</au><au>Horiuchi, Takahiko</au><au>Minota, Seiji</au><au>Ishigatsubo, Yoshiaki</au><au>Ota, Toshiyuki</au><au>Takei, Shuji</au><au>Soejima, Sachiko</au><au>Inoue, Hisako</au><au>Koarada, Syuichi</au><au>Tada, Yoshifumi</au><au>Nagasawa, Kohei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan</atitle><jtitle>Modern rheumatology</jtitle><stitle>Mod Rheumatol</stitle><addtitle>Mod Rheumatol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>22</volume><issue>5</issue><spage>712</spage><epage>719</epage><pages>712-719</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Objective
The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed.
Method
Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively.
Results
Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate.
Conclusion
Tocilizumab may be a promising biologic agent in refractory ASD.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>22160845</pmid><doi>10.1007/s10165-011-0569-6</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2012-09, Vol.22 (5), p.712-719 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1039882489 |
| source | Oxford Journals Online |
| subjects | Adolescent Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis C-Reactive Protein - analysis Child Drug Substitution Drug therapy Effectiveness Etanercept Female Ferritins - blood Humans Immunoglobulin G - therapeutic use Infliximab Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Original Article Orthopedics Patients Receptors, Tumor Necrosis Factor - therapeutic use Retrospective Studies Rheumatology Still's Disease, Adult-Onset - blood Still's Disease, Adult-Onset - drug therapy Treatment Outcome Young Adult |
| title | Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A01%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20response%20of%20patients%20with%20adult%20Still%E2%80%99s%20disease%20to%20biologic%20agents:%20multicenter%20results%20in%20Japan&rft.jtitle=Modern%20rheumatology&rft.au=Suematsu,%20Rie&rft.date=2012-09-01&rft.volume=22&rft.issue=5&rft.spage=712&rft.epage=719&rft.pages=712-719&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1007/s10165-011-0569-6&rft_dat=%3Cproquest_pubme%3E3004478821%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c383t-79a98b1d369160891dcf0bc511c4bd425caa66ba8e6c43133f41de591ff951063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1371042707&rft_id=info:pmid/22160845&rfr_iscdi=true |